[1] Gu YT, Chen J, Meng ZL, et al. Research progress on osteoarthritis treatment mechanisms[J]. Biomed Pharmacother, 2017, 93:1246-1252. [2] Rahmati M, Mobasheri A, Mozafari M. Inflammatory mediators in osteoarthritis:A critical review of the state-of-the-art, current prospects, and future challenges[J]. Bone, 2016, 85:81-90. [3] Lin CX, Shao Y, Zeng C, et al. Blocking PI3K/AKT signaling inhibits bone sclerosis in subchondral bone and attenuates post-traumatic osteoarthritis[J]. J Cell Physiol, 2018, 233(8):6135-6147. [4] Glyn-Jones S, Palmer AJR, Agricola R, et al. Osteoarthritis[J]. Lancet, 2015, 386(9991):376-387. [5] Hayami T, Pickarski M, Zhuo Y, et al. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis[J]. Bone, 2006, 38(2):234-243. [6] Li GY, Yin JM, Gao JJ, et al. Subchondral bone in osteoarthritis:Insight into risk factors and microstructural changes[J]. Arthritis Res Ther, 2013, 15(6):223. [7] Jiang YF, Sang WL, Wang C, et al. Oxymatrine exerts protective effects on osteoarthritis via modulating chondrocyte homoeostasis and suppressing osteoclastogenesis[J]. J Cell Mol Med, 2018, 22(8):3941-3954. [8] Ono T, Nakashima T. Recent advances in osteoclast biology[J]. Histochem Cell Biol, 2018, 149(4):325-341. [9] 平依林,娄锋,杨肖,等.Notch1蛋白高表达抑制破骨细胞增殖和分化[J].华西口腔医学杂志, 2016, 34(2):121-124. [10] Huang H, Ryu J, Ha J, et al. Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-κB transactivation by RANKL[J]. Cell Death Differ, 2006, 13(11):1879-1891. [11] Novack DV. Role of NF-κB in the skeleton[J]. Cell Res, 2011, 21(1):169-182. [12] Lee K, Chung YH, Ahn H, et al. Selective regulation of MAPK signaling mediates RANKL-dependent osteoclast differentiation[J]. Int J Biol Sci, 2016, 12(2):235-245. [13] Simutis FJ, Sanderson TP, Pilcher GD, et al. Nonclinical safety assessment of the γ-secretase inhibitor avagacestat[J]. Toxicol Sci, 2018,163(2):525-542. [14] Cai XF, Xing JJ, Long CL, et al. DOK3 modulates bone remodeling by negatively regulating osteoclastogenesis and positively regulating osteoblastogenesis[J]. J Bone Miner Res, 2017, 32(11):2207-2218. [15] Cho E, Chen ZH, Lee J, et al. PSTP-3, 5-me inhibits osteoclast differentiation and bone resorption[J]. Molecules, 2019, 24(18):3346. [16] Albright CF, Dockens RC, Meredith JE, et al. Pharmacodynamics of selective inhibition of γ-secretase by avagacestat[J]. J Pharmacol Exp Ther, 2013, 344(3):686-695. [17] Dockens R, Wang JS, Castaneda L, et al. A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects[J]. Clin Pharmacokinet, 2012, 51(10):681-693. [18] Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families[J]. Endocr Rev, 1999, 20(3):345-357. [19] Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis[J]. Nature, 1999, 397(6717):315-323. [20] Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function[J]. Nat Rev Genet, 2003, 4(8):638-649. [21] Matsuo K, Galson DL, Zhao C, et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos[J]. J Biol Chem, 2004, 279(25):26475-26480. [22] Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts[J]. Dev Cell, 2002, 3(6):889-901. [23] Duan L, de Vos P, Fan MW, et al. Notch is activated in RANKL-induced osteoclast differentiation and resorption[J]. Front Biosci, 2008, 13:7064-7071. [24] Yu J, Canalis E. Notch and the regulation of osteoclast differentiation and function[J]. Bone, 2020, 138:115474. [25] Huang Y, Mei W, Chen J, et al. Gamma-secretase inhibitor suppressed Notch1 intracellular domain combination with p65 and resulted in the inhibition of the NF-κB signaling pathway induced by IL-1β and TNF-α in nucleus pulposus cells[J]. J Cell Biochem, 2018,120(2):1903-1915. [26] Park DR, Ko R, Kwon SH, et al. FlexPro MD, a mixture of krill oil, astaxanthin, and hyaluronic acid, suppresses lipopolysaccharide-induced inflammatory cytokine production through inhibition of NF-κB[J]. J Med Food, 2016, 19(12):1196-1203. [27] Shi Y, Hu X, Cheng J, et al. A small molecule promotes cartilage extracellular matrix generation and inhibits osteoarthritis development[J]. Nat Commun, 2019, 10(1):1914. |